ATE501128T1 - 1,2,3-triazolamidderivate als inhibitoren der cytokinproduktion - Google Patents

1,2,3-triazolamidderivate als inhibitoren der cytokinproduktion

Info

Publication number
ATE501128T1
ATE501128T1 AT04812750T AT04812750T ATE501128T1 AT E501128 T1 ATE501128 T1 AT E501128T1 AT 04812750 T AT04812750 T AT 04812750T AT 04812750 T AT04812750 T AT 04812750T AT E501128 T1 ATE501128 T1 AT E501128T1
Authority
AT
Austria
Prior art keywords
triazolamide
inhibitors
derivatives
cytokine production
compounds
Prior art date
Application number
AT04812750T
Other languages
English (en)
Inventor
Derek Cogan
Daniel Goldberg
Abdelhakim Hammach
Matthew Netherton
Ronald Aungst
Original Assignee
Boehringer Ingelheim Pharma
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Boehringer Ingelheim Pharma filed Critical Boehringer Ingelheim Pharma
Application granted granted Critical
Publication of ATE501128T1 publication Critical patent/ATE501128T1/de

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • A61P11/06Antiasthmatics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00Drugs for skeletal disorders
    • A61P19/02Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00Drugs for skeletal disorders
    • A61P19/08Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/04Centrally acting analgesics, e.g. opioids
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/08Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04Antibacterial agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/02Immunomodulators
    • A61P37/06Immunosuppressants, e.g. drugs for graft rejection
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/10Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D249/00Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms
    • C07D249/02Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms not condensed with other rings
    • C07D249/041,2,3-Triazoles; Hydrogenated 1,2,3-triazoles
    • C07D249/061,2,3-Triazoles; Hydrogenated 1,2,3-triazoles with aryl radicals directly attached to ring atoms
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D403/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D405/00Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D413/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Rheumatology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Immunology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Diabetes (AREA)
  • Pain & Pain Management (AREA)
  • Biomedical Technology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pulmonology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Vascular Medicine (AREA)
  • Transplantation (AREA)
  • Emergency Medicine (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Endocrinology (AREA)
  • Obesity (AREA)
  • Dermatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
AT04812750T 2003-12-03 2004-12-01 1,2,3-triazolamidderivate als inhibitoren der cytokinproduktion ATE501128T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US52656903P 2003-12-03 2003-12-03
PCT/US2004/040306 WO2005056535A1 (en) 2003-12-03 2004-12-01 1,2,3-triazole amide derivatives as inhibitors of cytokine production

Publications (1)

Publication Number Publication Date
ATE501128T1 true ATE501128T1 (de) 2011-03-15

Family

ID=34676630

Family Applications (1)

Application Number Title Priority Date Filing Date
AT04812750T ATE501128T1 (de) 2003-12-03 2004-12-01 1,2,3-triazolamidderivate als inhibitoren der cytokinproduktion

Country Status (8)

Country Link
US (1) US7511042B2 (de)
EP (1) EP1692116B1 (de)
JP (1) JP4824576B2 (de)
AT (1) ATE501128T1 (de)
CA (1) CA2547410C (de)
DE (1) DE602004031759D1 (de)
ES (1) ES2360292T3 (de)
WO (1) WO2005056535A1 (de)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2265596T3 (es) * 2002-11-27 2007-02-16 Boehringer Ingelheim Pharmaceuticals Inc. Derivados de 1,2,3-triazol-amida como inhibidores de citocinas.
US7485657B2 (en) * 2004-05-12 2009-02-03 Boehringer Ingelheim Pharmaceuticals, Inc. Anti-cytokine heterocyclic compounds
US7531560B2 (en) * 2004-11-10 2009-05-12 Boehringer Ingelheim Pharmaceuticals, Inc. Anti-cytokine heterocyclic compounds
EP1867331A4 (de) * 2005-04-06 2009-04-08 Takeda Pharmaceutical Triazol-derivat und seine verwendung
BRPI0613881A2 (pt) * 2005-07-25 2011-02-15 Hoffmann La Roche derivados de triazol substituìdo e seu uso como antagonistas de receptor de neuroquinina 3
EP2041116A1 (de) * 2006-07-07 2009-04-01 Boehringer Ingelheim International GmbH Phenyl substituierte heteroaryl-derivate und deren verwendung als antitumormittel
EP2176249A2 (de) * 2007-07-02 2010-04-21 Boehringer Ingelheim International GmbH Neue chemische verbindungen
PE20090837A1 (es) * 2007-07-02 2009-07-24 Boehringer Ingelheim Int Nuevos compuestos quimicos
TW201014860A (en) 2008-09-08 2010-04-16 Boehringer Ingelheim Int New chemical compounds
JP5603869B2 (ja) 2008-09-29 2014-10-08 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング 新規化合物
WO2010094695A1 (en) 2009-02-17 2010-08-26 Boehringer Ingelheim International Gmbh Pyrimido [5,4-d] pyrimidine derivatives for the inhibition of tyrosine kinases
WO2011117382A1 (en) 2010-03-26 2011-09-29 Boehringer Ingelheim International Gmbh Pyridyltriazoles
EP2552905B1 (de) 2010-03-26 2016-10-05 Boehringer Ingelheim International GmbH Inhibitoren der B-Raf Kinase
US8710055B2 (en) 2010-12-21 2014-04-29 Boehringer Ingelheim International Gmbh Triazolylphenyl sulfonamides as serine/threonine kinase inhibitors
US8889684B2 (en) 2011-02-02 2014-11-18 Boehringer Ingelheim International Gmbh Azaindolylphenyl sulfonamides as serine/threonine kinase inhibitors
CN108715585A (zh) * 2018-04-23 2018-10-30 中国药科大学 苯基联三氮唑类mll1-wdr5蛋白-蛋白相互作用抑制剂
JP2024016314A (ja) * 2020-12-24 2024-02-07 小野薬品工業株式会社 一般式(i-a)で示される化合物、その薬学的に許容される塩、またはそれらの水和物と免疫チェックポイント阻害薬および/またはep4受容体拮抗薬との組み合わせ
CN115403533B (zh) * 2021-05-28 2023-08-25 永康市第一人民医院 一种1-苯乙烯基-1,2,3-三氮唑化合物及其制备方法和应用
WO2023177593A1 (en) * 2022-03-14 2023-09-21 Huyabio International, Llc Phenyl triazole mll1-wdr5 protein-protein interaction inhibitor

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0051084A1 (de) * 1980-11-04 1982-05-12 American Cyanamid Company Substituierte 1H-1,2,4-Triazole
DE4302051A1 (de) 1993-01-26 1994-07-28 Thomae Gmbh Dr K 5-gliedrige Heterocyclen, Verfahren zu ihrer Herstellung und diese Verbindungen enthaltende Arzneimittel
FR2732967B1 (fr) 1995-04-11 1997-07-04 Sanofi Sa 1-phenylpyrazole-3-carboxamides substitues, actifs sur la neurotensine, leur preparation, les compositions pharmaceutiques en contenant
KR100779889B1 (ko) * 1998-03-09 2007-11-28 다케다 야쿠힌 고교 가부시키가이샤 시클로알켄 유도체, 그의 제조 방법 및 용도
AU3387999A (en) 1998-04-08 1999-10-25 Abbott Laboratories Pyrazole inhibitors of cytokine production
PL346854A1 (en) 1998-09-25 2002-03-11 Astrazeneca Ab Benzamide derivatives and their use as cytokine inhibitors
BR9915534B1 (pt) 1998-10-23 2011-04-19 1-piridil substituìdo)-1,2,4-triazóis inseticidas.
MY133845A (en) * 2000-03-10 2007-11-30 Smithkline Beecham Corp Il-8 receptor antagonists
US6451820B1 (en) * 2000-03-23 2002-09-17 Boehringer Ingelheim Pharmaceuticals, Inc. Substituted 1-(4-aminophenly)triazoles and their use as anti-inflammatory agents
US6498423B1 (en) 2001-06-27 2002-12-24 Welch Allyn, Inc. Lamp thermal control by directed air flow
WO2003022820A1 (en) 2001-09-06 2003-03-20 Bristol-Myers Squibb Pharma Company. Heteroaromatic substituted cyclopropane as corticotropin releasing hormone
JP4445262B2 (ja) 2001-10-09 2010-04-07 アムジェン インコーポレイテッド 抗炎症剤としてのイミダゾール誘導体
US20040248956A1 (en) 2002-01-29 2004-12-09 Hagmann William K Substituted imidazoles as cannabinoid receptor modulators
ES2265596T3 (es) * 2002-11-27 2007-02-16 Boehringer Ingelheim Pharmaceuticals Inc. Derivados de 1,2,3-triazol-amida como inhibidores de citocinas.
RU2342365C2 (ru) * 2003-05-01 2008-12-27 Бристол-Маерс Сквибб Компани Арилзамещенные пиразоламиды в качестве ингибиторов киназ

Also Published As

Publication number Publication date
WO2005056535A1 (en) 2005-06-23
US7511042B2 (en) 2009-03-31
CA2547410A1 (en) 2005-06-23
JP4824576B2 (ja) 2011-11-30
EP1692116B1 (de) 2011-03-09
JP2007513167A (ja) 2007-05-24
CA2547410C (en) 2013-07-30
WO2005056535A8 (en) 2006-06-15
US20050153972A1 (en) 2005-07-14
ES2360292T3 (es) 2011-06-02
EP1692116A1 (de) 2006-08-23
DE602004031759D1 (de) 2011-04-21

Similar Documents

Publication Publication Date Title
ATE501128T1 (de) 1,2,3-triazolamidderivate als inhibitoren der cytokinproduktion
TW200508225A (en) Cytokine inhibitors
ATE433447T1 (de) Pyrimiidinverbindungen
SE0301373D0 (sv) Novel compounds
YU63703A (sh) 6-supstituisani pirido-pirimidini
MXPA03010724A (es) Compuestos de carbamato y oxamida como inhibidores de la produccion de citocina.
ATE296826T1 (de) Pyrazolo(1,5)pyridinderivate
SE0202133D0 (sv) Novel compounds
ATE361288T1 (de) N-(3,-dimethylindolin-6-yl)ä2-ä(4-
MXPA05012837A (es) Inhibidores de caspasa y usos de los mismos.
SE0101675D0 (sv) Novel composition
ATE440087T1 (de) 2,4-diaminopyrimidinderivate, die sich als inhibitoren von pkc-theta eignen
NO20064763L (no) Forbindelser og fremgangsmater for behandling av dyslipidemi
YU37904A (sh) Benzimidazoli kao korisni inhibitori proteinske kinaze
ATE329909T1 (de) 1,2,3-triazolamid-derivate als cytokininhibitoren
NO20043016L (no) 6-aminomorfinan-derivater, fremgangsmate for fremstilling og anvendelse derav
DE60332717D1 (de) Heterocyclische amid-derivate als cytokin-inhibitoren
BR0318521A (pt) arilindenopiridinas e arilindenopirimidinas e métodos terapêuticos e profiláticos relacionados
DK1362045T3 (da) 2-Thio-substituerede imidazolderivater og deres anvendelse inden for farmacien
WO2004075846A3 (en) Pyrazolopurine-based tricyclic compounds and pharmaceutical compositions comprising same
ES2182035T3 (es) Derivados del bisarilciclobuteno como inhibidores de ciclooxigenasa.
MXPA04000036A (es) Benzofuranos sustituidos con (hetero) arilo como ligandos 5-ht.
ATE419242T1 (de) Pyrrolidinylharnstoffderivate als angiogeneseinhibitoren
MXPA04005151A (es) Compuestos terapeuticos.
DE60318320D1 (de) Benzimidazolone und ihre verwendung als cytokininhibitoren

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 1692116

Country of ref document: EP